TBI TrueBlue (TBI) Insider Trading, Ownership & Congress Trades
Services · Services-help supply services · CIK 0000768899
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
59
13F, latest reported quarter
What the filings say about TBI
Insiders, 180 days
-$14.7K net sold
1 seller · 0% of sales under a 10b5-1 plan
TrueBlue insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, TrueBlue, Inc. insiders sold a net $14.7K of stock across 22 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 6, 2023.
- The trade is 3.0% of the 72,733 shares held after it.
- No other insider sold within 30 days.
- 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lontoh Sonita sold about $14.7K of TBI on Jun 5, 2026, the largest insider sale at the company since 2023; 59 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on May 1, 2023.
- The trade is 3.0% of the 234,135 shares held after it.
- 2 other insiders bought within 30 days.
- 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Legal Officer Ferencz Garrett bought about $25.3K of TBI on Feb 25, 2026; 2 other insiders bought within 30 days and 59 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Feb 26, 2025.
- +17.0% median (+17.0% mean) 90-day return after 2 previous buys.
- The trade is 2.6% of the 791,807 shares held after it.
- 2 other insiders bought within 30 days.
- 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Owen Taryn R bought about $77.3K of TBI on Feb 24, 2026, the largest insider purchase at the company since 2023; 2 other insiders bought within 30 days and 59 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (2 buys, 2 sales), the last on Mar 12, 2025.
- +8.1% median (+8.1% mean) 90-day return after 2 previous buys.
- The trade is 4.3% of the 289,069 shares held after it.
- 2 other insiders bought within 30 days.
- 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP and CFO Schweihs Carl bought about $46.5K of TBI on Feb 23, 2026; 2 other insiders bought within 30 days and 59 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Feb 24, 2025.
- The trade is 1.5% of the 169,051 shares held after it.
- 1 other insider bought within 30 days.
- 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP and CFO Schweihs Carl bought about $13.1K of TBI on Mar 12, 2025; 1 other insider bought within 30 days and 59 funds added in the latest 13F quarter.22 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$14.7K over 180 days
more than 69% of Services
Congress
no House purchase disclosed in the last 12 months
Funds
59 funds bought in last quarter
below 60% of Services
Revenue
+3.1% year over year
below 58% of Services
Margin
-3.0% net margin
below 64% of Services
Buybacks
no share repurchases reported
Short interest
1.5% of the float short (float per yahoo 2026-10-27) · 2.1 days to cover · settled 2026-10-15
below 62% of Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TBI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+70.7%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TBI: institutional holders (13F)
13F holdings, latest reported quarter
3,090,808 sh
$21.5M
2,792,612 sh
$19.5M
2,478,866 sh
$17.3M
2,230,995 sh
$15.6M
1,285,839 sh
$9.0M
Congress trades in TBI
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TBI planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
TBI mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Pzena Small Cap Value Fund
$883.3K position · as of 2026-05-31
0.9%
Ultra-Small Company Fund
$902.6K position · as of 2026-06-30
0.9%
WPG Partners Select Small Cap Value Fund
$2.0M position · as of 2026-05-31
0.9%
Palm Valley Capital Fund
$1.2M position · as of 2026-06-30
0.6%
Dunham Small Cap Value Fund
$460.5K position · as of 2026-07-31
0.5%
Royce Capital Fund - Micro-Cap Portfolio
$686.5K position · as of 2026-06-30
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Trueblue, Inc. Political Action Committee
Cycle 2026 · $3K spent
$27.4K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Ms Owen
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$3.8M
$2.2M
$1.4M
-59%
+42%
2021
$5.8M
$9.9M
$2.1M
+44%
+47%
2020
$3.4M
$2.0M
$1.2M
-19%
+3%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $14.7K sold by insiders over 180 days, 59 funds added last quarter. Each figure is a federal filing, dated the day it went public.
TBI financials
Revenue growth
+3.1%
XBRL, annual
Net margin
-3.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.7B
four quarters, 2025-06-30 to 2026-06-28
Revenue, TTM TBI
| FY Dec 2025 | $1.6B |
| FY Dec 2024 | $1.6B |
| FY Dec 2023 | $1.9B |
| FY Dec 2022 | $2.3B |
| FY Dec 2021 | $2.2B |
| Jun 2026 | $443.0M |
| Mar 2026 | $398.6M |
| Dec 2025 | $418.2M |
| Sep 2025 | $431.3M |
| Jun 2025 | $396.3M |
| Mar 2025 | $370.3M |
| Dec 2024 | $386.0M |
| Sep 2024 | $382.4M |
At each fiscal year end
Single quarter
Net margin, TTM
-3.3%
net income over revenue, 2025-06-30 to 2026-06-28
Net margin, TTM TBI
| FY Dec 2025 | -3.0% |
| FY Dec 2024 | -8.0% |
| FY Dec 2023 | -0.7% |
| FY Dec 2022 | +2.8% |
| FY Dec 2021 | +2.8% |
| Jun 2026 | -0.8% |
| Mar 2026 | -5.0% |
| Dec 2025 | -7.5% |
| Sep 2025 | -0.4% |
| Jun 2025 | -0.0% |
| Mar 2025 | -3.9% |
| Dec 2024 | -3.0% |
| Sep 2024 | -2.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$67.4M
operating cash flow minus capex, 2025-06-30 to 2026-06-28
Free cash flow, TTM TBI
| FY Dec 2025 | -$73.7M |
| FY Dec 2024 | -$41.2M |
| FY Dec 2023 | $3.5M |
| FY Dec 2022 | $89.9M |
| FY Dec 2021 | -$14.6M |
| Jun 2026 | -$24.0M |
| Mar 2026 | -$12.6M |
| Dec 2025 | -$7.5M |
| Sep 2025 | -$23.4M |
| Jun 2025 | -$16.1M |
| Mar 2025 | -$26.8M |
| Dec 2024 | $854.0K |
| Sep 2024 | -$12.7M |
At each fiscal year end
Single quarter
Debt to equity
0.43x
long-term 2026-06-28 plus current 2020-06-28 (73 months older than the period end); equity 2026-06-28
Debt to equity TBI
| FY Dec 2025 | 0.34x |
| FY Dec 2024 | 0.11x |
| FY Dec 2023 | 0.06x |
| FY Dec 2022 | 0.06x |
| FY Dec 2021 | 0.05x |
| Jun 2026 | 0.43x |
| Mar 2026 | 0.39x |
| Dec 2025 | 0.34x |
| Sep 2025 | 0.31x |
| Jun 2025 | 0.26x |
| Mar 2025 | 0.28x |
| Dec 2024 | 0.11x |
| Sep 2024 | 0.08x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.50x
TTM operating cash flow over long-term 2026-06-28 plus current 2020-06-28 (73 months older than the period end)
Cash flow to debt TBI
| FY Dec 2025 | -0.63x |
| FY Dec 2024 | -0.49x |
| FY Dec 2023 | 1.28x |
| FY Dec 2022 | 3.88x |
| FY Dec 2021 | 0.76x |
| Jun 2026 | -0.50x |
| Mar 2026 | -0.45x |
| Dec 2025 | -0.63x |
| Sep 2025 | -0.50x |
| Jun 2025 | -0.43x |
| Mar 2025 | -0.29x |
| Dec 2024 | -0.49x |
| Sep 2024 | -0.30x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-20.2%
TTM net income over average of 2025-06-29 and 2026-06-28
Return on equity TBI
| FY Dec 2025 | -16.3% |
| FY Dec 2024 | -32.5% |
| FY Dec 2023 | -3.0% |
| FY Dec 2022 | +12.6% |
| FY Dec 2021 | +13.3% |
| Jun 2026 | -20.2% |
| Mar 2026 | -19.1% |
| Dec 2025 | -16.3% |
| Sep 2025 | -8.9% |
| Jun 2025 | -10.5% |
| Mar 2025 | -37.0% |
| Dec 2024 | -32.5% |
| Sep 2024 | -29.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-8.7%
TTM net income over average of 2025-06-29 and 2026-06-28
Return on assets TBI
| FY Dec 2025 | -7.3% |
| FY Dec 2024 | -16.0% |
| FY Dec 2023 | -1.5% |
| FY Dec 2022 | +6.1% |
| FY Dec 2021 | +6.1% |
| Jun 2026 | -8.7% |
| Mar 2026 | -8.1% |
| Dec 2025 | -7.3% |
| Sep 2025 | -4.0% |
| Jun 2025 | -4.8% |
| Mar 2025 | -17.7% |
| Dec 2024 | -16.0% |
| Sep 2024 | -14.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital TBI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +13.2% |
| FY Dec 2021 | +13.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-9.6%
operating income (EBIT proxy) over average of 2025-06-29 and 2026-06-28 minus current liabilities
Return on capital employed TBI
| FY Dec 2025 | -9.2% |
| FY Dec 2024 | -15.3% |
| FY Dec 2023 | -3.2% |
| FY Dec 2022 | +9.3% |
| FY Dec 2021 | +9.2% |
| Jun 2026 | -9.6% |
| Mar 2026 | -9.9% |
| Dec 2025 | -9.2% |
| Sep 2025 | -5.1% |
| Jun 2025 | -6.3% |
| Mar 2025 | -15.0% |
| Dec 2024 | -15.3% |
| Sep 2024 | -14.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing TBI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 10.33x |
| FY Dec 2021 | 15.80x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$385.5M
market value at close 2026-10-26 on 2026-07-26 shares, plus long-term 2026-06-28 plus current 2020-06-28 (73 months older than the period end), minus cash 2026-06-28
Enterprise value TBI
| FY Dec 2025 | $207.6M |
| FY Dec 2024 | $244.7M |
| FY Dec 2023 | $442.8M |
| FY Dec 2022 | $587.8M |
| FY Dec 2021 | $958.2M |
| Jun 2026 | $298.7M |
| Mar 2026 | $176.3M |
| Dec 2025 | $207.6M |
| Sep 2025 | $261.9M |
| Jun 2025 | $257.8M |
| Mar 2025 | $227.9M |
| Dec 2024 | $244.7M |
| Sep 2024 | $239.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-22.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield TBI
| FY Dec 2025 | -53.0% |
| FY Dec 2024 | -17.7% |
| FY Dec 2023 | +0.7% |
| FY Dec 2022 | +14.3% |
| FY Dec 2021 | -1.5% |
| Jun 2026 | -31.7% |
| Mar 2026 | -59.8% |
| Dec 2025 | -53.0% |
| Sep 2025 | -35.0% |
| Jun 2025 | -27.5% |
| Mar 2025 | -27.9% |
| Dec 2024 | -17.7% |
| Sep 2024 | -15.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing TBI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 1.64x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.6B | $1.6B | $1.9B | $2.3B |
| Gross profit | $367.8M | $406.4M | $506.1M | $602.1M |
| Operating income | -$46.6M | -$92.8M | -$23.9M | $72.2M |
| Net income | -$48.0M | -$125.7M | -$14.2M | $62.3M |
| EPS (diluted) | -1.61 | -4.17 | -0.45 | 1.86 |
| Operating cash flow | -$58.0M | -$17.1M | $34.8M | $120.5M |
| Cash | $24.5M | $22.5M | $61.9M | $72.1M |
| Long-term debt | $65.8M | $7.6M | $0 | n/a |
| Buybacks | $0 | $21.3M | $34.2M | $60.9M |
SEC XBRL, fiscal years, as known on 2026-10-28
TBI Stock Sonar score 6/7 axes
Find similar shapesCompareTBI ranks highest on growth (42nd percentile) and institutional and government (41st), and lowest on profitability (27th), among Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TBI filings, in plain words
Are TrueBlue insiders buying or selling TBI?
In the 180 days to 2026-10-28, TrueBlue insiders were net sellers, a net $14.7K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, TrueBlue insiders were net sellers of TBI, a net $14.7K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
